Biotech pioneer Galapagos officially adopted the name Lakefront Biotherapeutics™ NV on 8 May 2026, marking a new stage in one of Europe’s most notable biotech transformation journeys.
Established in 1999 as a joint venture between Crucell and Tibotec under the leadership of founder and former CEO Onno van de Stolpe, Galapagos evolved from a small Belgian-Dutch biotechnology startup into a globally recognized life sciences company listed on both Euronext and Nasdaq. Throughout its history, the company gained recognition for its robust research platform, its landmark partnership with Gilead Sciences, and the introduction of the rheumatoid arthritis treatment Jyseleca.
In more recent years, the company has experienced a major strategic shift. Under its second CEO, Paul Stoffels, who joined in 2022, Galapagos broadened its focus into oncology and advanced cell therapy through the acquisitions of CellPoint and AboundBio. It later sold its Jyseleca business to concentrate on innovative therapies in immunology and oncology.
After conducting a comprehensive strategic review and responding to changing market dynamics, the company gradually moved away from its cell therapy strategy and embraced a new approach focused on transformative business development and selective investments in novel therapeutic opportunities.
The new name, Lakefront Biotherapeutics™, reflects this repositioning. According to the company, the rebrand represents “a forward-looking identity grounded in clarity, discipline, and ambition,” while underscoring its commitment to building a portfolio of breakthrough opportunities for patients and generating long-term value for stakeholders.
This transition marks the end of a significant chapter in European biotechnology while ushering in a new era for one of the Benelux region’s most recognized life sciences companies.